Ambeed.cn

首页 / / / / (-)-Gallocatechin

没食子儿茶素 /(-)-Gallocatechin {[allProObj[0].p_purity_real_show]}

货号:A335376 同义名: (-)-棓儿茶酸 / Q-100410;J-500978

(-)-gallocatechin是一种天然多酚化合物,通过清除自由基和螯合金属离子表现出强抗氧化活性。此外,(-)-Gallocatechin 可抑制与炎症相关的关键酶(如 COX-2),并调节 NF-κB 等信号通路,从而发挥抗炎作用。

(-)-Gallocatechin 化学结构 CAS号:3371-27-5
(-)-Gallocatechin 化学结构
CAS号:3371-27-5
(-)-Gallocatechin 3D分子结构
CAS号:3371-27-5
(-)-Gallocatechin 化学结构 CAS号:3371-27-5
(-)-Gallocatechin 3D分子结构 CAS号:3371-27-5
规格 价格 会员价 库存 数量
{[ item.pr_size ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price) ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price) ]}
{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} 现货 1周 咨询 - +
购物车0 收藏 询单

(-)-Gallocatechin 纯度/质量文件 产品仅供科研

货号:A335376 标准纯度: {[allProObj[0].p_purity_real_show]}
批次查询: 批次纯度:

全球学术期刊中引用的产品

ACS Appl. Nano Mater., 2025. Ambeed. [ A188026 ]
Eur. J. Clin. Microbiol. Infect. Dis., 2025. Ambeed. [ A151161 ]
JJC, 2025, 20(Special Issue)): 27-39. Ambeed. [ A713856 ]
bioRxiv, 2025. Ambeed. [ A538667 , A714873 , A126729 , A126049 , A446054 ]
Nature Communications, 2025, 16, 1871. Ambeed. [ A508148 ]
更多 >
产品名称 CB1 CB2 其他靶点 纯度
Otenabant HCl ++++

rCB1, Ki: 2.8 nM

hCB1, Ki: 0.7 nM

98+%
AM251 98%
Rimonabant +++

hCB1, IC50: 13.6 nM

++

hCB2, IC50: 1.64 μM

99%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。

(-)-Gallocatechin 生物活性

描述 (-)-Gallocatechin, a natural product isolated and purified from the wood of Acacia catechu (L.F.) Willd., has moderate affinity to the human cannabinoid receptor. E. brasiliensis has an important anti-inflammatory activity, and that this effect by the presence of the compounds catechin and gallocatechin[3]. GC (gallocatechin) -AgNPs (silver nanoparticles)-CGP dressing on diabetic wound rats modulated oxidative stress and inflammation with elevated growth factors; increased collagen synthesis thereby significantly improved the wound healing and could be beneficial for the management of diabetic wounds[4]. BC (baicalin) and GC (gallocatechin) produced concentration-dependent anti-aggregation effects with GC producing a more pronounced effect than BC[5].

(-)-Gallocatechin 临床研究

NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT01360320 Colorectal Serrated Adenomas ... 展开 >> Colorectal Tubular Adenomas Colorectal Villous Adenomas Colorectal Tubulovillous Adenomas 收起 << Phase 2 Unknown March 2018 Germany ... 展开 >> Ostalb-Klinikum Aalen, Medizinische Klinik 1, Sekretariat Prof. Kleber Recruiting Aalen, Germany, 73430 Contact: Caroline Walny       caroline.walny@ostalb-klinikum.de    Principal Investigator: Gerhard Kleber, MD          Klinikum Altenburger Land, Gastroenterologie Not yet recruiting Altenburg, Germany, 04600 Contact: Michael Repp, MD       michael.repp@klinikum-altenburgerland.de    Principal Investigator: Michael Repp, MD          Klinikum Augsburg, III. Med. Klinik Recruiting Augsburg, Germany, 86156 Contact: Tanja Hilmer       Tanja.Hilmer@klinikum-augsburg.de    Krankenhaus Bietigheim-Bissingen, Klinik für Innere Medizin, Gastroenterologie, Hämato-Onkologie Recruiting Bietigheim-Bissingen, Germany, 74321 Contact: Ulla Hegmann       hegmul01@kliniken-lb.de    Principal Investigator: Siegfried Walker, MD          Krankenhaus Buchholz, Abteilung Innere Medizin Recruiting Buchholz, Germany, 21244 Contact: Dirk Fahrenholz, MD       Dirk.Fahrenholz@krankenhaus-buchholz.de    Principal Investigator: Dirk Fahrenholz, MD          Kliniken der Stadt Köln gGmbH, Krankenhaus Holweide -Medizinische Klinik- Recruiting Cologne, Germany Contact: Claudia Kaiser-Stolz       Kaiser-Stolz@kliniken-koeln.de    Principal Investigator: Ulrich Huegle, MD          Klinikum Esslingen, Klinik für Innere Medizin, Onkologie, Gastroenterologie Recruiting Esslingen, Germany, 73730 Contact: Stephanie Klink       s.klink@kliniken-es.de    Principal Investigator: Michael Geissler, MD          Universitätsklinikum der Ernst-Moritz-Arndt-Universität Greifswald, Klinik und Poliklinik für Innere Medizin A Recruiting Greifswald, Germany, 17475 Contact: Eckhard Weber       eckhard.weber@uni-greifswald.de    Principal Investigator: Julia Mayerle, MD          Dr. Zeisler, Praxis für Innere Medizin und Gastroenterologie Recruiting Halle, Germany, 06108 Contact: Brigitte Schneider       gastrozeisler@yahoo.de    Principal Investigator: Thomas Zeisler, MD          Dres. Fechner/Behrens/Steudel - Gastroenterologisch-Onkologische Praxisklinik Recruiting Halle, Germany, 06108 Contact: Anja Schlenk       bsf@gastro-halle.de    Principal Investigator: Ruediger Behrens, MD          Dr. Frank-Gleich Praxis für Innere Medizin und Gastroenterologie Recruiting Halle, Germany, 06110 Contact: Ute Kabisch       u.kabisch@onkomedic.de    Principal Investigator: Stefanie Frank-Gleich, MD          Universitätsklinikum Halle, Klinik für Innere Medizin I Recruiting Halle, Germany, 06120 Contact: Teuber Evelin       evelin.teuber@medizin.uni-halle.de    Principal Investigator: Thomas Seufferlein, MD          Sub-Investigator: Thomas J. Ettrich, MD          Klinikum Ludwigsburg, Medizinische Klinik I Recruiting Ludwigsburg, Germany, 71640 Contact: Samuel Raad       samuel.raad@kliniken-lb.de    Principal Investigator: Karel Caca, MD          Diakoniekrankenhaus Mannheim, Medizinische Klinik II Recruiting Mannheim, Germany, 68163 Contact: Ulrich Damian, MD       u.damian@diako-ma.de    Principal Investigator: Ulrich Damian, MD          II. Medizinische Klinik und Poliklinik der TU München, Klinikum rechts der Isar Recruiting Munich, Germany, 81675 Contact: Jens Zimmermann       Studiensekretariat.med2@lrz.tum.de    Principal Investigator: Jens T. Siveke, MD          Klinik Mühldorf Abt.Gastroenterologie Recruiting Mühldorf am Inn, Germany, 84453 Contact: Melanie Mühlberger       melanie.muehlberger@kliniken-muehldorf.de    Principal Investigator: Gerhard Fuechsl, MD          Klinikum Bogenhausen, Interdisziplinäre Onkologische Tagklinik Recruiting München, Germany, 81525 Contact: Romy Petermann       romy.petermann@klinikum-muenchen.de    Principal Investigator: Martin Fuchs, MD          Regio Kliniken Pinneberg Not yet recruiting Pinneberg, Germany, 25421 Contact: Stefan Tardos, MD       stefan.tardos@regiokliniken.de    Principal Investigator: Stefan Tardos, MD          Klinikum St. Elisabeth, I. Medizinische Klinik Recruiting Straubing, Germany, 94315 Contact: Stefanie Wolf       stefanie.wolf@klinikum-straubing.de    Principal Investigator: Weigert Norbert, MD          Universitätsklinikum Ulm, Klinik für Innere Medizin I Recruiting Ulm, Germany, 89081 Contact: Yvonne Kriebisch       yvonne.kriebisch@uniklinik-ulm.de    Principal Investigator: Goetz von Wichert, MD          Evangelisches Krankenhaus Wesel, Abteilung Innere Medizin Recruiting Wesel, Germany, 46485 Contact: Adelheid Rosendahl       rosendahl@evkwesel.de    Principal Investigator: Dirk Hartnack, MD 收起 <<
NCT00253643 Precancerous Condition ... 展开 >> Prostate Cancer 收起 << Not Applicable Completed - United States, Oregon ... 展开 >> Kaiser Permanente Center for Health Research Portland, Oregon, United States, 97227 OHSU Knight Cancer Institute Portland, Oregon, United States, 97239-3098 Veterans Affairs Medical Center - Portland Portland, Oregon, United States, 97239 收起 <<
NCT00917735 Breast Cancer Phase 2 Completed - United States, Minnesota ... 展开 >> Fairview Southdale Breast Center Edina, Minnesota, United States, 55435 Fairview Maple Grove Breast Center Maple Grove, Minnesota, United States, 55369 University of Minnesota Medical Center (UMMC) Breast Clinic Minneapolis, Minnesota, United States, 55455 Park Nicollet Institute St. Louis Park, Minnesota, United States, 55426 Food Science and Nutrition, University of Minnesota St. Paul, Minnesota, United States, 55108 收起 <<

(-)-Gallocatechin 参考文献

[1]Hui X, Hua SH, et al. Antimicrobial mechanism of epigallocatechin gallate and gallocatechin gallate: They target 1-deoxy-d-xylulose 5-phosphate reductoisomerase, the key enzyme of the MEP terpenoid biosynthetic pathway. Arch Biochem Biophys. 2017 May 15;622:1-8.

[2]Takagaki A, Nanjo F. Biotransformation of (-)-epigallocatechin and (-)-gallocatechin by intestinal bacteria involved in isoflavone metabolism. Biol Pharm Bull. 2015;38(2):325-30.

[3]Siebert DA, Paganelli CJ, Queiroz GS, Alberton MD. Anti-inflammatory activity of the epicuticular wax and its isolated compounds catechin and gallocatechin from Eugenia brasiliensis Lam. (Myrtaceae) leaves. Nat Prod Res. 2021 Nov;35(22):4720-4723

[4]Vendidandala NR, Yin TP, Nelli G, Pasupuleti VR, Nyamathulla S, Mokhtar SI. Gallocatechin‑silver nanoparticle impregnated cotton gauze patches enhance wound healing in diabetic rats by suppressing oxidative stress and inflammation via modulating the Nrf2/HO-1 and TLR4/NF-κB pathways. Life Sci. 2021 Dec 1;286:120019

[5]Sohail A, Bhat WF, Bhat SA, Furkan M, Shah A, Bano B. Investigating the preventive effects of baicalin and gallocatechin against glyoxal-induced cystatin aggregation. J Biomol Struct Dyn. 2018 Nov;36(14):3791-3802

(-)-Gallocatechin 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.27mL

0.65mL

0.33mL

16.33mL

3.27mL

1.63mL

32.65mL

6.53mL

3.27mL

(-)-Gallocatechin 技术信息

CAS号3371-27-5
分子式C15H14O7
分子量 306.26
别名 (-)-棓儿茶酸 ;Q-100410;J-500978;AK-64755
运输蓝冰
存储条件

In solvent -20°C:3-6个月-80°C:12个月

Pure form Sealed in dry,2-8°C

溶解方案

DMSO: 105 mg/mL(342.84 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO

H2O: 1.5 mg/mL(4.9 mM),配合低频超声,并水浴加热至45℃助溶

请根据您的动物给药指南选择适当的溶解方案。
以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂:
——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
方案一
方案二
动物实验配方
Ambeed 相关网站 Ambeed.cn Ambeed.com
Ambeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
  • 客户支持
    技术支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    积分商城
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    Ambeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务,不为任何个人或者非科研性质用途提供服务。